Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Cooley Advised Silence Therapeutics on Agreement to Be Acquired By Merck KGaA ...

19 October 2026 · By · Wire by Fusion42

Published

19 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United Kingdom

◆ Source

Read at cooley.com →

◆ Verified

Fusion42 · 19 October 2026 · Fusion42 review

Cooley advised Silence Therapeutics on its $1.3 billion acquisition agreement by Merck KGaA, Darmstadt, Germany, acquiring all outstanding shares in an all-cash deal that includes the phase 3-ready siRNA therapy Divesiran.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

The high-value buyout by Merck KGaA signals growing pharma interest in siRNA medicines, making it urgent for biotech founders in RNA therapies to re-evaluate partnerships and competitive positioning now.

◆ Coverage

2 sources · 19 Oct 2026

◆ Related on Wire

◆ Topics

Biotechm&abiotechsiRNAmerck-kgaaclinical-stageacquisition